Nippon Chemiphar To Out-license Rights To Gout Drug Candidate
This article was originally published in PharmAsia News
Executive Summary
Nippon Chemiphar has decided to out-license the rights to its new gout drug candidate NC-2500, instead of developing and commercializing it on its own